Dear Molecular Imaging Insider,
When we asked Dr. Stefano Fanti to nominate the area of molecular imaging that offers the greatest clinical potential, his reply was refreshingly clear and concise: PET. He thinks new radiopharmaceuticals will eventually be used in many clinical settings outside of oncology, from neurology to infective disease. Also, in radiological training, much greater emphasis should be put on functional imaging, he said.
We interviewed Dr. Fanti in advance of this month's annual congress of the European Association of Nuclear Medicine. To read about his views, visit the Molecular Imaging Digital Community, or click here.
We also put a very similar set of questions to Dr. Fabian Kiessling, from Aachen in Germany. His answers provide further insight about the future of molecular imaging, and you can read them here.
PET/CT may hold significant clinical promise, but it also has its own potential pitfalls and difficulties in interpretation. To assist you in this task, researchers from a leading cancer hospital have offered some advice, and to get it, click here.
Errors in PET-guided planning of intensity-modulated radiation therapy can be avoided by using advanced segmentation algorithms, according to French researchers. Use of these algorithms helps maintain patient safety and quality in a radiation oncology department. Get the story here.
Dr. Henry Wagner Jr. was a global pioneer in the field of nuclear medicine and past president of the U.S. Society of Nuclear Medicine and Molecular Imaging. He died on 25 September at the age of 85. Click here to learn more about him.
The World Molecular Imaging Congress took place in Dublin last month, and science writer Cormac Sheridan covered the meeting for us. If you missed his news reports from the event, go to the Molecular Imaging Digital Community, looking out for the letters "WMIC" at the start of the headline.
